The master switch: The role of mast cells in autoimmunity and tolerance

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 705-739

  Sayed, Blayne A ^a   Christy, Alison ^a   Quirion, Mary R ^a   Brown, Melissa A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adaptive immunity; EAE; Hypersensitivity responses; Mast cells; MS

Indexed keywords

ALLOXAN; CIMETIDINE; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; HEPARIN; HISTAMINE; IMATINIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 4; LEUKOTRIENE; NERVE GROWTH FACTOR; PROSTAGLANDIN; SALBUTAMOL; SEROTONIN; STEM CELL FACTOR RECEPTOR; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ALLERGIC REACTION; ALLERGY; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CLINICAL FEATURE; DELAYED HYPERSENSITIVITY; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; MAST CELL; MEDIATOR RELEASE; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNITY; HUMANS; HYPERSENSITIVITY; MAST CELLS; MODELS, IMMUNOLOGICAL; SELF TOLERANCE;

EID: 42649118758     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090320     Document Type: Review

References (201)

1. Galli SJ, Lantz CS. 1999. Allergy. In Fundamental Immunology, ed. WE Paul, pp. 1137-84. Philadelphia: Lippincott-Raven. 4th ed.
2. Marshall JS. 2004. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4:787-99
3. Galli SJ, Nakae S, Tsai M. 2005. Mast cells in the development of adaptive immune responses. Nat. Immunol. 6:135-42
4. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23:749-86
5. Metcalfe DD, Baram D, Mekori YA. 1997. Mast cells. Physiol. Rev. 77:1033-79
6. Johnson D, Krenger W. 1992. Interactions of mast cells with the nervous system - recent advances. Neurochem. Res. 17:939-51
7. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, et al. 2001. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 14:801-11
8. Bachelet I, Levi-Schaffer F. 2007. Mast cells as effector cells: a costimulating question. Trends Immunol. 28:360-65
9. Tashiro M, Kawakami Y, Abe R, Han W, Hata D, et al. 1997. Increased secretion of TNF-alpha by costimulation of mast cells via CD28 and Fcε RI. J. Immunol. 158:2382-89
10. Nishimoto H, Lee SW, Hong H, Potter KG, Maeda-Yamamoto M, et al. 2005. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 106:4241-48
11. Qiao H, Andrade MV, Lisboa FA, Morgan K, Beaven MA. 2006. FcεR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 107:610-18
12. Malbec O, Daeron M. 2007. The mast cell IgG receptors and their roles in tissue inflammation. Immunol. Rev. 217:206-21
13. Katz HR. 2007. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol. Rev. 217:222-30
14. Wong JMX, Roberts D, Bartley PA, Jackson DE. 2002. Absence of platelet endothelial cell adhesion molecule-1 (CD31) leads to increased severity of local and systemic IgE-mediated anaphylaxis and modulation of mast cell activation. J. Immunol. 168:6455-62
15. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, et al. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176:2238-48
16. + T lymphocytes. Eur. J. Immunol. 26:2517-28
17. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, et al. 1993. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340-43
18. Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. 2007. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J. Invest. Dermatol. 127:2605-11
19. Ludgate M, Baker G. 2002. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin. Exp. Immunol. 127:193-98
20. Okayama Y, Kirshenbaum AS, Metcalfe DD. 2000. Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: up-regulation by IFN-γ. J. Immunol. 164:4332-39
21. Redegeld FA, van der Heijden MW, Kool M, Heijdra BM, Garssen J, et al. 2002. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat. Med. 8:694-701
22. Edelson BT, Stricker TP, Li Z, Dickeson SK, Shepherd VL, et al. 2006. Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood 107:143-50
23. Echtenacher B, Mannel DN, Hultner L. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77
24. Prodeus AP, Zhou X, Maurer M, Galli SJ, Carroll MC. 1997. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390:172-75
25. Marshall JS, King CA, McCurdy JD. 2003. Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr. Pharm. Des. 9:11-24
26. Szalai AJ, Hu X, Adams JE, Barnum SR. 2007. Complementin experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol. Immunol. 44:3132-36
27. Urich E, Gutcher I, Prinz M, Becher B. 2006. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc. Natl. Acad. Sci. USA 103:18697-702
28. Akira S, Takeda K, Kaisho T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-80
29. Matsushima H, Yamada N, Matsue H, Shimada S. 2004. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol. 173:531-41
30. Feng BS, He SH, Zheng PY, Wu L, Yang PC. 2007. Mast cells play a crucial role in Staphylococcus aureus peptidoglycan-induced diarrhea. Am. J. Pathol. 171:537-47
31. Narita S, Goldblum RM, Watson CS, Brooks EG, Estes DM, et al. 2007. Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environ. Health Perspect. 115:48-52
32. Vasiadi M, Kempuraj D, Boucher W, Kalogeromitros D, Theoharides TC. 2006. Progesterone inhibits mast cell secretion. Int. J. Immunopathol. Pharmacol. 19:787-94
33. Theoharides TC, Kalogeromitros D. 2006. The critical role of mast cells in allergy and inflammation. Ann. NY Acad. Sci. 1088:78-99
34. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. 2007. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217:65-78
35. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. 1982. Differential release of serotonin and histamine from mast cells. Nature 297:229-31
36. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, et al. 2003. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J. Immunol. 171:4830-36
37. -sh mice as a model for investigating mast cell biology in vivo. Am. J. Pathol. 167:835-48
38. v mice and their increase by bone marrow transplantation. Blood 52:447-52
39. v mice. J. Exp. Med. 162:1025-43
40. Marrack P, Kappler J, Kotzin BL. 2001. Autoimmune disease: Why and where it occurs. Nat. Med. 7:899-905
41. Nelson KC, Zhao M, Schroeder PR, Li N, Wetsel RA, et al. 2006. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J. Clin. Invest. 116:2892-900
42. Levi-Schaffer F, Klapholz L, Kupietzky A, Weinrauch L, Shalit M, Okon E. 1991. Increased numbers of mast cells in pemphigus vulgaris skin lesions. A histochemical study. Acta Derm.-Venereol. 71:269-71
43. Juurikivi A, Sandler C, Lindstedt KA, Kovanen PT, Juutilainen T, et al. 2005. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann. Rheum. Dis. 64:1126-31
44. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. 2002. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297:1689-92
45. Secor VH, Secor WE, Gutekunst CA, Brown JMA. 2000. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191:813-22
46. Geoffrey R, Jia S, Kwitek AE, Woodliff J, Ghosh S, et al. 2006. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J. Immunol. 177:7275-86
47. Brosman CF, Lyman WD, Tansey FA, Carter TH. 1985. Quantitation of mast cells in experimental allergic neuritis. J. Neuropathol. Exp. Neurol. 44:196-203
48. Seeldrayers PA, Yasui D, Weiner HL, Johnson D. 1989. Treatment of experimental al lergic neuritis with nedocromil sodium. J. Neuroimmunol. 25:221-26
49. Konttinen YT, Hietanen J, Virtanen I, Ma J, Sorsa T, et al. 2000. Mast cell derangement in salivary glands in patients with Sjogren's syndrome. Rheumatol. Int. 19:141-47
50. Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. 1998. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br. J. Dermatol. 138:399-406
51. Shiota N, Kakizoe E, Shimoura K, Tanaka T, Okunishi H. 2005. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br. J. Pharmacol. 145:424-31
52. Walker M, Harley R, LeRoy EC. 1990. Ketotifen prevents skin fibrosis in the tight skin mouse. J. Rheumatol. 17:57-59
53. Walker JMA, Harley RA, LeRoy EC. 1987. Inhibition of fibrosis in TSK mice by blocking mast cell degranulation. J. Rheumatol. 14:299-301
54. Kiely PD, Pecht I, Oliveira DB. 1997. Mercuric chloride-induced vasculitis in the Brown Norway rat: αβ T cell-dependent and -independent phases: role of the mast cell. J. Immunol. 159:5100-6
55. Grimbaldeston JMA, Metz M, Yu M, Tsai M, Galli SJ. 2006. Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr. Opin. Immunol. 18:751-60
56. Leighty L, Li N, Diaz LA, Liu Z. 2007. Experimental models for the autoimmune and inflammatory blistering disease, bullous pemphigoid. Arch. Dermatol. Res. 299:417-22
57. Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA, et al. 2001. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 108:1151-58
58. Kayashima K, Koji T, Nozawa M, Ono T, Nakane PK. 1998. Activation of bullous pemphigoid antigen gene in mouse ear epidermis by UV radiation. Cell Biochem. Funct. 16:107-16
59. Endoh I, Di Girolamo N, Hampartzoumian T, Cameron B, Geczy CL, Tedla N. 2007. Ultraviolet B irradiation selectively increases the production of interleukin-8 in human cord blood-derived mast cells. Clin. Exp. Immunol. 148:161-67
60. Dimson OG, Giudice GJ, Fu CL, Van den Bergh F, Warren SJ, et al. 2003. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J. Invest. Dermatol. 120:784-88
61. Borrego L, Maynard B, Peterson EA, George T, Iglesias L, et al. 1996. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am. J. Pathol. 148:897-909
62. Stassi G, De Maria R. 2002. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat. Rev. Immunol. 2:195-204
63. Prabhakar BS, Bahn RS, Smith TJ. 2003. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr. Rev. 24:802-35
64. Yamada T, Sato A, Aizawa T, Ootsuka H, Miyahara Y, et al. 1998. An elevation of stem cell factor in patients with hyperthyroid Graves' disease. Thyroid 8:499-504
65. Many MC, Costagliola S, Detrait M, Denef F, Vassart G, Ludgate MC. 1999. Development of an animal model of autoimmune thyroid eye disease. J. Immunol. 162:4966-74
66. Arthus M. 1903. Injections repetées de serum de cheval cuez le lapin. C. R. Soc. Biol. 55:817-20
67. Ravetch JV, Bolland S. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-90
68. Zhang Y, Ramos BF, Jakschik BA. 1991. Augmentation of reverse Arthus reaction by mast cells in mice. J. Clin. Invest. 88:841-46
69. Sylvestre DL, Ravetch JV. 1996. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 5:387-90
70. Ramos BF, Zhang Y, Qureshi R, Jakschik BA. 1991. Mast cells are critical for the production of leukotrienes responsible for neutrophil recruitment in immune complex-induced peritonitis in mice. J. Immunol. 147:1636-41
71. Zhang Y, Ramos F, Jakschik B. 1992. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 258:1957-59
72. Feldmann M, Brennan FM, Maini RN. 1996. Rheumatoid arthritis. Cell 85:307-10
73. Dorner T, Egerer K, Feist E, Burmester GR. 2004. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 16:246-53
74. Sakaguchi S, Sakaguchi N. 2005. Animal models of arthritis caused by systemic alteration of the immune system. Curr. Opin. Immunol. 17:589-94
75. Ecklund K. 2007. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for antirheumatic therapy. Immunol. Rev. 217:38-52
76. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, et al. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 196:77-85
77. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, et al. 2007. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc. Natl. Acad. Sci. USA 104:2325-30
78. Nigrovic PA, Lee DM. 2007. Synovial mast cells: role in acute and chronic arthritis. Immunol. Rev. 217:19-37
79. Kneilling M, Hultner L, Pichler BJ, Mailhammer R, Morawietz L, et al. 2007. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum. 56:1806-16
80. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, et al. 2006. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116:2633-42
81. Shlomchik MJ, Craft JE, Mamula MJ. 2001. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1:147-53
82. Hiromura K, Kurosawa M, Yano S, Naruse T. 1998. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am. J. Kidney Dis. 32:593-99
83. Satoh M, Kumar A, Kanwar YS, Reeves WH. 1995. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc. Natl. Acad. Sci. USA 92:10934-38
84. Satoh M, Reeves WH. 1994. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J. Exp. Med. 180:2341-46
85. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. 1998. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188:985-90
86. v mice to pristane-induced experimental lupus nephritis. Immunol. Lett. 91:93-97
87. van Loveren H, Meade R, Askenase PW. 1983. An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J. Exp. Med. 157:1604-17
88. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, et al. 2000. Mast cells control neutrophil recruitment duringT cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J. Exp. Med. 192:1441-52
89. Sospedra M, Martin R. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683-747
90. Miller SD, Shevach EM. 1998. Immunoregulation of experimental autoimmune encephalomyelitis: editorial overview. Res. Immunol. 149:753-59
91. Vanderlugt CL, Miller SD. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2:85-95
92. Sriram S, Steiner I. 2005. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 58:939-45
93. Steinman L, Zamvil SS. 2005. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26:565-71
94. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, et al. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156:5-7
95. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233-40
96. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179-89
97. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-32
98. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-41
99. Ibrahim MZM, Reder AT, Lawand R, Takash W, Sallouh-Khatib S. 1996. The mast cells of the multiple sclerosis brain. J. Neuroimmunol. 70:131-38
100. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. 1995. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann. Neurol. 37:63-66
101. Tuomisto L, Kilpelainen H, Riekkinen P. 1983. Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis. Agents Actions 13:255-55
102. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-8
103. Gregory GD, Robbie-Ryan M, Secor VH, Sabatino JJ Jr, Brown MA. 2005. Mast cells are required for optimal autoreactive T cell responses in a murine model of multiple sclerosis. Eur. J. Immunol. 35:3478-86
104. Tanzola MB, Robbie-Ryan M, Gutekunst CA, Brown MA. 2003. Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course. J. Immunol. 171:4385-91
105. McDevitt H. 2001. Closing in on type 1 diabetes. N. Engl. J. Med. 345:1060-61
106. Rees DA, Alcolado JC. 2005. Animal models of diabetes mellitus. Diabet. Med. 22:359-70
107. Esposito I, Friess H, Kappeler A, Shrikhande S, Kleeff J, et al. 2001. Mast cell distribution and activation in chronic pancreatitis. Hum. Pathol. 32:1174-83
108. Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, et al. 2002. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab. Invest. 82:1481-92
109. Zimnoch L, Szynaka B, Puchalski Z. 2002. Mast cells and pancreatic stellate cells in chronic pancreatitis with differently intensified fibrosis. Hepatogastroenterology 49:1135-38
110. Parlapiano C, Danese C, Marangi M, Campana E, Pantone P, et al. 1999. The relationship between glycated hemoglobin and polymorphonuclear leukocyte leukotriene B4 release in people with diabetes mellitus. Diabetes Res. Clin. Pract. 46:43-45
111. + T cell levels in NOD mice. Proc. Natl. Acad. Set. USA 99:12287-92
112. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9:1202-8
113. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, et al. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203:883-95
114. Hughes RA, Cornblath DR. 2005. Guillain-Barre syndrome. Lancet 366:1653-66
115. Yu RK, Usuki S, Ariga T. 2006. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect. Immun. 74:6517-27
116. Maurer M, Gold R. 2002. Animal models of immune-mediated neuropathies. Curr. Opin. Neurol. 15:617-22
117. Pilartz M, Jess T, Indefrei D, Schroder JM. 2002. Adoptive transfer-experimental allergic neuritis in newborn Lewis rats results in inflammatory infiltrates, mast cell activation, and increased Ia expression with only minor nerve fiber degeneration. Acta Neuropathol. 104:513-24
118. Varga J, Abraham D. 2007. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117:557-67
119. Arnett FC. 2006. Is scleroderma an autoantibody mediated disease? Curr. Opin. Rheumatol. 18:579-81
120. Ozbilgin MK, Inan S. 2003. The roles of transforming growth factor type β3 (TGF-β3) and mast cells in the pathogenesis of scleroderma. Clin. Rheumatol. 22:189-95
121. Wang HW, Tedla N, Hunt JE, Wakefield D, McNeil HP. 2005. Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp. Dermatol. 14:295-302
122. Bouma G, Strober W. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521-33
123. King T, Biddle W, Bhatia P, Moore J, Miner PB Jr. 1992. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig. Dis. Sci. 37:490-95
124. Oshitani N, Kamata N, Inagawa M, Yamagami H, Watanabe K, et al. 2006. Significance of activated mast cells in submucosa and muscularis propria of patients with Crohn's disease detected by a novel antimast cell surface molecule antibody. Aliment. Pharmacol. Ther. 24(Suppl. 4):1-7
125. Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. 1995. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int. Arch. Allergy Immunol. 108:127-33
126. Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. 1999. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 44:643-52
127. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, et al. 2001. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am. J. Pathol. 159:1751-61
128. Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, et al. 2001. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease. Gut 49:795-803
129. Kapsenberg ML. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3:984-93
130. Regner M, Lambert PH. 2001. Autoimmunity through infection or immunization? Nat. Immunol. 2:185-88
131. Sayed BA, Brown MA. 2007. Mast cells as modulators of T-cell responses. Immunol. Rev. 217:53-64
132. Wu L, Liu YJ. 2007. Development of dendritic-cell lineages. Immunity 26:741-50
133. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. 2006. Mast cell-associated TNF promotes dendritic cell migration. J. Immunol. 176:4102-12
134. Harizi H, Gualde N. 2006. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol. Immunol. 3:271-77
135. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, et al. 2003. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat. Immunol. 4:1199-205
136. Jawdat DM, Rowden G, Marshall JS. 2006. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol. 177:1755-62
137. Gutzmer R, Diestel C, Mommert S, Kother B, Stark H, et al. 2005. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J. Immunol. 174:5224-32
138. Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, et al. 2001. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J. Immunol. 167:3682-86
139. Kitawaki T, Kadowaki N, Sugimoto N, Kambe N, Hori T, et al. 2006. IgE-activated mast cells in combination with proinflammatory factors induce Th2-promoting dendritic cells. Int. Immunol. 18:1789-99
140. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. 2001. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J. Clin. Invest. 108:1865-73
141. Shin EH, Lee HY, Bae YS. 2006. Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. Biochem. Biophys. Res. Commun. 348:606-11
142. Del Prete A, Shao WH, Mitola S, Santoro G, Sozzani S, Haribabu B. 2007. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 109:626-31
143. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. 2000. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103:757-68
144. Jozefowski S, Biedron R, Bobek M, Marcinkiewicz J. 2005. Leukotrienes modulate cytokine release from dendritic cells. Immunology 116:418-28
145. Theiner G, Gessner A, Lutz MB. 2006. The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 211:463-72
146. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. 2006. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol. 176:966-73
147. McIlroy A, Caron G, Blanchard S, Fremaux I, Duluc D, et al. 2006. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-γ-induced CXCL10 production by immature human dendritic cells. Immunology 117:507-16
148. Sa-Nunes A, Bafica A, Lucas DA, Conrads TP, Veenstra TD, et al. 2007. Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva. J. Immunol. 179:1497-505
149. Yao Y, Li W, Kaplan MH, Chang CH. 2005. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J. Exp. Med. 201:1899-903
150. Teloni R, Giannoni F, Rossi P, Nisini R, Gagliardi MC. 2007. Interleukin-4 inhibits cyclooxygenase-2 expression and prostaglandin E production by human mature dendritic cells. Immunology 120:83-89
151. + T cells. J. Immunol. 174:7433-39
152. + regulatory T cells. Proc. Natl. Acad. Sci. USA 104:2821-26
153. Sato K, Kawasaki H, Nagayama H, Enomoto M, Morimoto C, et al. 2000. TGF-β 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164:2285-95
154. Borkowski TA, Letterio JJ, Farr AG, Udey MC. 1996. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β 1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184:2417-22
155. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, et al. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213-23
156. Katoh N, Soga F, Nara T, Tamagawa-Mineoka R, Nin M, et al. 2006. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin. Exp. Immunol. 146:354-61
157. a+ dendritic cells from monocytes: phenotypic and functional characterization. J. Immunol. 168:1131-38
158. Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC. 2004. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 20:381-92
159. Nagai H, Inagaki N, Tanaka H. 1999. Role of IgE for the onset of allergic cutaneous response caused by simple chemical hapten in mice. Int. Arch. Allergy Immunol. 118:285-86
160. Jawdat DM, Mbert EJ, Rowden G, Haidl ID, Marshall JS. 2004. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J. Immunol. 173:5275-82
161. Akdis CA, Blaser K. 2003. Histamine in the immune regulation of allergic inflammation. J. Allergy Clin. Immunol. 112:15-22
162. Mazzoni A, Leifer CA, Mullen GE, Kennedy MN, Klinman DM, Segal DM. 2003. Cutting edge: Histamine inhibits IFN-α release from plasmacytoid dendritic cells. J. Immunol. 170:2269-73
163. Amaral MM, Davio C, Ceballos A, Salamone G, Canones C, et al. 2007. Histamine improves antigen uptake and cross-presentation by dendritic cells. J. Immunol. 179:3425-33
164. Mazzoni A, Siraganian RP, Leifer CA, Segal DM. 2006. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J. Immunol. 177:3577-81
165. Gregory GD, Raju SS, Winandy S, Brown MA. 2006. Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE. J. Clin. Invest. 116:1327-36
166. Yang XD, McDevitt HO. 1994. Role of TNF-α in the development of autoimmunity and the pathogenesis of insulin-dependent diabetes mellitus in NOD mice. Circ. Shock 43:198-201
167. Gilliet M, Soumelis V, Watanabe N, Hanabuchi S, Antonenko S, et al. 2003. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. J Exp. Med. 197:1059-63
168. Frandji P, Oskeritzian C, Cacraci F, Lapeyre J, Peronet R, et al. 1993. Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J. Immunol. 151:6318-28
169. Fox CC, Jewell SD, Whitacre CC. 1994. Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell. Immunol. 158:253-64
170. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, et al. 2001. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413:420-25
171. Steinman L. 2001. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. J. Exp. Med. 194:F27-30
172. Tang XL, Smith TR, Kumar V. 2005. Specific control of immunity by regulatory CD8 T cells. Cell Mol. Immunol. 2:11-19
173. Gombert M, Dieu-Nosjean MC, Winterberg F, Bunemann E, Kubitza RC, et al. 2005. CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J. Immunol. 174:5082-91
174. Kaur D, Saunders R, Berger P, Siddiqui S, Woodman L, et al. 2006. Mrway smooth muscle and mast cell-derived CCL19 mediate airway smooth muscle migration in asthma. Am. J. Respir. Crit. Care Med. 174:1179-88
175. Humrich JY, Humrich JH, Averbeck M, Thumann P, Termeer C, et al. 2006. Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration. Immunology 117:238-47
176. Kivisakk P, Mahad DJ, Callahan MK, Sikora K, Trebst C, et al. 2004. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 55:617-38
177. + T(H)-17 cells in relapsing EAE. Nat. Immunol. 8:172-80
178. Engelhardt B. 2006. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J. Neural. Transm. 113:477-85
179. + T cell-mediated, mast cell-dependent airway hyperresponsiveness. J. Immunol. 176:3157-64
180. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. 2003. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol. 4:974-81
181. Di Girolamo N, Indoh I, Jackson N, Wakefield D, McNeil HP, et al. 2006. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J. Immunol. 177:2638-50
182. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-80
183. Shevach EM. 2006. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25:195-201
184. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, et al. 2000. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106:R75-81
185. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27:18-20
186. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, et al. 2006. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002
187. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. 2007. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with UV B. Nat. Immunol. 8:1095-104
188. Johnson D, Seeldrayers PA, Weiner HL. 1988. The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation. Brain Res. 44:195-98
189. O'Brien PJ, Molino M, Kahn M, Brass LF. 2001. Protease activated receptors: theme and variations. Oncogene 20:1570-81
190. Johnson D, Yasui D, Seeldrayers P. 1991. An analysis of mast cell frequency in the rodent nervous system: Numbers vary between different strains and can be reconstituted in mast cell-deficient mice. J. Neuropathol. Exp. Neurol. 50:227-34
191. Skokos D, Goubran-Botros H, Roa M, Mecheri S. 2002. Immunoregulatory properties of mast cell-derived exosomes. Mol. Immunol. 38:1359-62
192. Tkaczyk C, Frandji P, Botros HG, Poncet P, Lapeyre J, et al. 1996. Mouse bone marrow-derived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. J. Immunol. 157:1720-28
193. Banu Y, Watanabe T. 1999. Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling. J. Exp. Med. 189:673-82
194. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, et al. 2005. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J. Immunol. 174:7665-75
195. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, et al. 2004. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145:43-48
196. Cao J, Cetrulo CL, Theoharides TC. 2006. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol. Pharmacol. 69:998-1006
197. Micera A, Lambiase A, Rama P, Moe L. 1999. Altered nerve growth factor level in the optic nerve of patients affected by multiple sclerosis. Mult. Scler. 5:389-94
198. Micera A, Vigneti E, Aloe L. 1998. Changes of NGF presence in nonneuronal cells in response to experimental allergic encephalomyelitis in Lewis rats. Exp. Neurol. 154:41-46
199. Arredondo LR, Deng C, Ratts RB, Lovett-Racke AE, Holtzman DM, Racke MK 2001. Role of nerve growth factor in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 31:625-33
200. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. 1996. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 19:514-20
201. Zhang J, Li Y, Lu M, Cui Y, Chen J, et al. 2006. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J. Neurosci. Res. 84:587-95